Literature DB >> 18080292

Developmental loss of NT-3 in vivo results in reduced levels of myelin-specific proteins, a reduced extent of myelination and increased apoptosis of Schwann cells.

Adele G Woolley1, Karen J Tait, Bradley J Hurren, Lorryn Fisher, Philip W Sheard, Marilyn J Duxson.   

Abstract

This work investigates the role of NT-3 in peripheral myelination. Recent articles, based in vitro, propose that NT-3 acting through its high-affinity receptor TrkC may act to inhibit myelin formation by enhancing Schwann cell motility and/or migration. Here, we investigate this hypothesis in vivo by examining myelination formation in NT-3 mutant mice. On the day of birth, soon after the onset of myelination, axons showed normal ensheathment by Schwann cells, no change in the proportion of axons which had begun to myelinate, and no change in either myelin thickness or number of myelin lamellae. However in postnatal day 21 mice, when myelination is substantially complete, we observed an unexpected reduction in mRNA and protein levels for MAG and P(0), and in myelin thickness. This is the opposite result to that predicted from previous in vitro studies, where removal of an inhibitory NT-3 signal would have been expected to enhance myelination. These results suggest that, in vivo, the importance of NT-3 as a major support factor for Schwann cells (Meier et al., (1999) J Neurosci 19:3847-3859) over-rides its potential role as an myelin inhibitor, with the net effect that loss of NT-3 results in degradation of Schwann cell functions, including myelination. In support of this idea, Schwann cells of NT-3 null mutants showed increased expression of activated caspase-3. Finally, we observed significant reduction in width of the Schwann cell periaxonal collar in NT-3 mutant animals suggesting that loss of NT-3 and resulting reduction in MAG levels may alter signaling at the axon-glial interface.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18080292     DOI: 10.1002/glia.20614

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  14 in total

Review 1.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

2.  Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.

Authors:  Lu Q Le; Chiachi Liu; Tracey Shipman; Zhiguo Chen; Ueli Suter; Luis F Parada
Journal:  Cancer Res       Date:  2011-05-06       Impact factor: 12.701

Review 3.  Signals to promote myelin formation and repair.

Authors:  Carla Taveggia; Maria Laura Feltri; Lawrence Wrabetz
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

4.  Neurotrophin treatment to promote regeneration after traumatic CNS injury.

Authors:  Lakshmi Kelamangalath; George M Smith
Journal:  Front Biol (Beijing)       Date:  2013-10-01

5.  Peripheral Nerve Regeneration by Secretomes of Stem Cells from Human Exfoliated Deciduous Teeth.

Authors:  Yukiko Sugimura-Wakayama; Wataru Katagiri; Masashi Osugi; Takamasa Kawai; Kenichi Ogata; Kohei Sakaguchi; Hideharu Hibi
Journal:  Stem Cells Dev       Date:  2015-08-10       Impact factor: 3.272

Review 6.  New insights on Schwann cell development.

Authors:  Kelly R Monk; M Laura Feltri; Carla Taveggia
Journal:  Glia       Date:  2015-04-29       Impact factor: 7.452

Review 7.  Schwann cell interactions during the development of the peripheral nervous system.

Authors:  Emma R Wilson; Gustavo Della-Flora Nunes; Michael R Weaver; Luciana R Frick; M Laura Feltri
Journal:  Dev Neurobiol       Date:  2020-05-05       Impact factor: 3.102

8.  Enhancing proprioceptive input to motoneurons differentially affects expression of neurotrophin 3 and brain-derived neurotrophic factor in rat hoffmann-reflex circuitry.

Authors:  Olga Gajewska-Woźniak; Małgorzata Skup; Stefan Kasicki; Ewelina Ziemlińska; Julita Czarkowska-Bauch
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

9.  AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy.

Authors:  Zarife Sahenk; Gloria Galloway; Kelly Reed Clark; Vinod Malik; Louise R Rodino-Klapac; Brian K Kaspar; Lei Chen; Cilwyn Braganza; Chrystal Montgomery; Jerry R Mendell
Journal:  Mol Ther       Date:  2013-10-28       Impact factor: 11.454

10.  Nanoparticles carrying neurotrophin-3-modified Schwann cells promote repair of sciatic nerve defects.

Authors:  Haibin Zong; Hongxing Zhao; Yilei Zhao; Jingling Jia; Libin Yang; Chao Ma; Yang Zhang; Yuzhen Dong
Journal:  Neural Regen Res       Date:  2013-05-15       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.